SCHEMBL3287166

SCHEMBL3287166

COc1ccc(-c2ccc(-c3cc4ncccc4c(O)n3)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.70
NPC1 O15118 2/20 0.59
RAB9A P51151 1/20 0.59
ACP1 P24666 4/20 0.51
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
MAPT P10636 2/20 0.50
ACACA Q13085 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
IDH1 O75874 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
DHODH Q02127 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3281714 0.99 SYK (0.71) SYKNPC1RAB9AACP1KDM4E
SCHEMBL524076 0.83 SYK (0.53) SYKACACA
SCHEMBL3280663 0.82 SYK (0.71) SYKNPC1RAB9AACP1KDM4E
SCHEMBL11365024 0.82 SYK (1.00) SYKNPC1RAB9AACP1KDM4E
SCHEMBL10195960 0.82 SYK (0.52) SYKNPC1RAB9AKDM4EALDH1A1
SCHEMBL3281450 0.80 SYK (0.55) SYKKDM4EMAPTLMNAHTT
SCHEMBL590118 0.80 SYK (1.00) SYKNPC1RAB9AACP1KDM4E
SCHEMBL526640 0.80 SYK (0.64) SYK
SCHEMBL3281453 0.80 SYK (0.73) SYK
SCHEMBL8273110 0.79 NPC1 (0.58) SYKNPC1RAB9AACP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-12-11 US disclosed
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK SYK 1/4885NPC1 1817/4885RAB9A 851/4885
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 SYK 1/4885NPC1 1376/4885RAB9A 692/4885
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 SYK 1/4885NPC1 1304/4885RAB9A 759/4885
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK SYK 1/4885NPC1 1817/4885RAB9A 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.